Finance

Lists
Why is GIS up 2,10%?
Dive Deeper
GIS:FRA
Gilead Sciences, Inc
€153,52
+2,10%
(+3,16) 1D
20 Nov., 22:00:00 GMT+1  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for GIS...
Open
€152,16
High
€154,04
Low
€152,16
Mkt. cap
206,43 mjd.
Avg. vol.
276,00
Volume
790,00
52-wk high
€157,14
52-wk low
€100,42
No. of employees
17 k
Open
€152,16
High
€154,04
Low
€152,16
Mkt. cap
206,43 mjd.
Avg. vol.
276,00
Volume
790,00
52-wk high
€157,14
52-wk low
€100,42
No. of employees
17 k
News stories
From web sources and news partners
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy. In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade. In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100. The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
About Gilead Sciences, Inc
CEODaniel O'Day
Employees17 k
Founded22 Jun. 1987
HeadquartersFoster City, Kalifornië, Verenigde State van Amerika
SectorHealth Care
Industry-
Websitegilead.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Des. 2025
Mrt. 2026
Jun. 2026
Sep. 2026
Revenue
7,92 mjd.
6,96 mjd.
7,80 mjd.
8,30 mjd.
Cost of goods sold
1,62 mjd.
1,44 mjd.
1,58 mjd.
1,57 mjd.
Cost of revenue
1,62 mjd.
1,44 mjd.
1,58 mjd.
1,57 mjd.
Research and development expenses
1,57 mjd.
1,36 mjd.
1,69 mjd.
1,60 mjd.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,78 mjd.
1,43 mjd.
1,91 mjd.
1,61 mjd.
Operating expense
3,34 mjd.
2,78 mjd.
3,60 mjd.
3,21 mjd.
Total operating expenses
4,96 mjd.
4,23 mjd.
5,18 mjd.
4,78 mjd.
Operating income
2,96 mjd.
2,73 mjd.
2,63 mjd.
3,52 mjd.
Other non operating income
3,00 m.
-8,00 m.
-
-7,00 m.
EBT including unusual items
2,08 mjd.
2,58 mjd.
-10,25 mjd.
3,06 mjd.
EBT excluding unusual items
2,80 mjd.
2,59 mjd.
2,42 mjd.
3,29 mjd.
Income tax expense
-105,00 m.
559,00 m.
242,00 m.
634,00 m.
Effective tax rate
-5,05%
21,67%
-2,36%
20,70%
Other operating expenses
-
-
-
-
Net income
2,18 mjd.
2,02 mjd.
-10,50 mjd.
2,43 mjd.
Net profit margin
27,55%
29,04%
-134,51%
29,27%
Earnings per share
1,86
2,03
-6,75
2,55
Interest and investment income
95,00 m.
95,00 m.
45,00 m.
41,00 m.
Interest expense
-255,00 m.
-240,00 m.
-247,00 m.
-269,00 m.
Net interest expenses
-160,00 m.
-145,00 m.
-202,00 m.
-228,00 m.
Depreciation and amortization charges
-
-
-
-
EBITDA
3,65 mjd.
3,42 mjd.
3,33 mjd.
4,26 mjd.
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google-programme